
zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso is a zzso agent developed for use in cancer zzso It is zzso in zzso zzso by selectively zzso in cancer cells that have high rates of zzso zzso zzso zzso cellular zzso resulting in the production of zzso oxygen species and inducing zzso It is being developed by zzso in the zzso Bulk zzso zzso is supplied to zzso by the US company, zzso through a manufacturing and supply agreement between the two zzso In June 2003, at the 39th Annual Meeting of the American Society of Clinical Oncology zzso the importance of having an agent for the treatment of brain zzso from lung cancer was zzso zzso of a phase III study were presented that showed that zzso zzso treatment was associated with a delay in time to neurological and zzso progression in lung cancer zzso This was an important finding, as zzso of lung cancer patients already have brain zzso at the time of initial diagnosis, compared with only zzso of breast cancer zzso Brain zzso are also often the only site of zzso disease in patients with lung zzso In December 2002, zzso began a phase III trial of zzso zzso in patients with brain zzso zzso cancer in phase zzso from lung cancer in the zzso Europe, Canada and zzso The trial is known as the Study of zzso progression with zzso zzso And zzso zzso zzso and will compare zzso zzso with zzso zzso plus zzso zzso in 550 zzso The primary efficacy zzso is time to neurological progression and the secondary zzso are survival and zzso zzso In January 2003, the US zzso completed its Special zzso Assessment zzso of the SMART trial with a positive result and by June 2003, enrollment had zzso In addition, phase I trials are zzso in children with intrinsic zzso zzso and adults with head and neck, lung and pancreatic zzso A phase II trial is also being conducted in the US in patients with zzso zzso Enrollment in this trial has been completed and preliminary results have been zzso zzso has completed enrollment and follow-up of adults in its pivotal phase III trial of zzso zzso as a radiation zzso for the treatment of brain zzso The trial was conducted at 35 zzso in Europe, Canada and the zzso Full results from this initial phase III trial were presented at the annual meeting of the American Society of Clinical Oncology zzso in Orlando, Florida, USA, held in May zzso zzso also announced in October 2002, at the 44th Annual Meeting of the American Society for zzso zzso and Oncology zzso that zzso zzso significantly prolonged time to neurological progression when added to whole brain radiation therapy and reduced the number of deaths in patients with brain zzso zzso announced in September 2000 that it has initiated two zzso phase I trials conducted under a Cooperative Research and Development zzso zzso between zzso and the zzso The first trial, conducted in patients with stage zzso zzso cell lung cancer, was designed to determine the safety of two different dosing regimens of zzso zzso during zzso zzso after induction zzso The second study was designed to examine the use of zzso zzso in combination with zzso zzso zzso zzso in patients with primary zzso zzso Two phase I clinical trials have also been conducted for the treatment of newly diagnosed zzso zzso at the zzso zzso Comprehensive Cancer Center, zzso These phase I studies were sponsored by the zzso and were conducted under a zzso with the zzso zzso has also completed zzso US phase II clinical trials of zzso zzso fin zzso in patients with zzso zzso of the brain who require whole brain zzso zzso zzso is in a phase II trial in patients with zzso and multiple myeloma in the zzso 

